Diabetology: Feature Papers 2022

doi:10.3390/books978-3-0365-7257-4

Download Url(s)

https://mdpi.com/books/pdfview/book/7151

Contributor(s)

Clifton, Peter (editor)

Language

English

Show full item record

Abstract

As Editor-in-Chief of the journal Diabetology, I am pleased to announce that the Special Issue “Diabetology: Feature Papers 2022” has now been published as a reprint. Diabetology (ISSN 2673-4540) is an international, peer-reviewed scientific open access journal that provides an advanced forum for studies related to the epidemiology, etiology, pathophysiology, pathogenesis, management, complications, and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. In this Special Issue, “Feature Papers”, we aimed to publish outstanding contributions in the main fields covered by the journal, which will make a great contribution to the community. This reprint covers the whole spectrum of diabetology from risk screening, risk markers, pathways of disease in type 1 diabetes and insulin treatment, and management of the disease and comorbidities.

URI

https://directory.doabooks.org/handle/20.500.12854/100058

Keywords

older people; diabetes mellitus; management; insulin therapy; frailty; sarcopenia; type 1 diabetes; type 2 diabetes; insulin; beta cell preservation; verapamil; thioredoxin-interacting protein (TXNIP); Chronic Care Model; self-management of type 2 diabetes; chronic disease; healthcare system of Pakistan; patients’ quality of life; obstructive sleep apnoea; DM; obesity; inflammation; polysomnography; coronavirus disease 2019; COVID-19; severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; diabetes; diabetic ketoacidosis; DKA; hyperglycemia; mortality; innate immunity; cytokine storm; angiotensin-converting enzyme 2; pancreatic β-cell damage; pediatrics; HbA1c; telemedicine; continuous glucose monitoring; prediabetes; liver enzymes; rhenium (V) compound; triglycerides; NAFLD; fructose; injection technique; lipohypertrophy; sodium glucose co-transporter 2 (SGLT2) inhibitors; nocturia; sodium intake; key informant interviews; prevention of type 2 diabetes; National DPP; DSMES; telehealth; provider experiences; lipodystrophy; clinical detection; recommendations; rehabilitation